|
Real-time Estimate
Cboe BZX
18:17:25 24/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.615 USD | -3.29% |
|
-7.23% | +17.15% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 577 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 87.4% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 380.4 | 426.8 | 245.9 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | 9.63% | 12.18% | -42.39% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -2.77x | -2.6x | -2.98x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.44x | 2.9x | 1.29x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.41x | 0.2x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 170x | 47.7x | 6.82x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 112x | 35.3x | 2.9x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -1.9x | -1.78x | -0.91x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -1.91x | -1.83x | -1.13x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -3.01x | -2.92x | -1.96x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -33.2% | -34.2% | -51.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6036 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.4 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.1 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.670 | 1.670 | 1.670 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 14/03/24 | 13/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.77x | 111.9x | -1.9x | -.--% | 577M | |
| 21.81x | 7.74x | 15.55x | 1.36% | 74.18B | |
| 30.94x | 8.91x | 27.77x | 0.04% | 59.55B | |
| -72.24x | 13.96x | -67.31x | -.--% | 25.84B | |
| -15.16x | 5.72x | -7.19x | -.--% | 24.73B | |
| 28.65x | 5.38x | 17.91x | -.--% | 20.87B | |
| 44.32x | 16.25x | 32.97x | 0.34% | 15.32B | |
| 17.52x | 5.22x | 12.18x | -.--% | 14.06B | |
| -14.32x | 3225.89x | -16.49x | -.--% | 13.12B | |
| -81.25x | 7.42x | -61.47x | -.--% | 11.85B | |
| Average | -4.25x | 340.84x | -4.80x | 0.17% | 26.01B | |
| Weighted average by Cap. | 6.11x | 171.19x | 3.82x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
